3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Myelodysplastic Syndromes
1
Anemia
1
Interventions
emicizumab
4
voxelotor
1
romiplostim
1
recombinant FVIIa
1
olaparib
1
maltodextrin
1
lusutrombopag
1
luspatercept
1
ibrutinib
1
fludarabine phosphate
1
continuous erythropoietin receptor activator
1
betrixaban
1
anti-inhibitor coagulant complex
1
Rituximab
1
Pharmacogenomic Testing
1
Glutamine
1
Factor VIII
1
Enoxaparin
1
Cyclophosphamide
1
CT-P10
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
luspatercept
×
Classical hematology
×
Clear all
NCT02631070
2021-12-17
MEDALIST
Celgene
Phase 3
Completed
229 enrolled
36 charts
1 FDA